24 hours treatment of anti-B220 MSN-DN on B220+ AML LSCs at lower drug concentrations achieved maximum killing in contrast to free DN, indicating better efficacy of DN loaded into functionalised MSNs (Supplementary Fig. S2). Here, PTPRC is linked to acute myeloid leukemia.